Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients with Chronic Hepatitis C Infection

Theodor Bilharz Research Institute

Bibliographic Information

Authors: Yakoot M.; El-Shabrawi M.H.; Abdelgawad M.M.; Mahfouz A.A.; Helmy S.; Abdo A.M.; El-Khayat H.R.

Journal: Journal of Pediatric Gastroenterology and Nutrition

Publisher: Lippincott Williams and Wilkins

Publication Date: July 2018

Volume / Issue: Volume 67 / Issue 1

Pages: 86–89

ISSN: 2772116

DOI: 10.1097/MPG.0000000000001968

Scopus: View on Scopus

PubMed: 29570560

Document Type: Article


Authors and Affiliations

Yakoot M., Internal Medicine and Hepatology, Green CRC, 27 Green Street, Alexandria, 21121, Egypt; El-Shabrawi M.H., Paediatric Hepatology Department, Cairo Faculty of Medicine, Cairo, Egypt; Abdelgawad M.M., Paediatric Hepatology Department, Alexandria Faculty of Medicine, Alexandria, Egypt; Mahfouz A.A., Paediatric Hepatology Department, Alexandria Faculty of Medicine, Alexandria, Egypt; Helmy S., Innovations and Research, Pharco Corporation, Alexandria, Egypt; Abdo A.M., Tropical Medicine and Hepatology Department, Alexandria Faculty of Medicine, Alexandria, Egypt; El-Khayat H.R., Gastroenterology and Endemic Medicine Department, Theodore Research Institute, Cairo, Egypt


Abstract

Objectives: Dual sofosbuvir/daclatasvir (SOF/DCV) therapy is currently recommended by the European Association for Study of Liver (EASL) as an option for the treatment of chronic hepatitis C virus (HCV) infection in adults for all genotypes; however, it is still not considered for patients younger than 18 years old. We aimed to test safety and efficacy of SOF/DCV in adolescent patients 12 to 17 years old with chronic HCV, genotype 4 infection. Methods: We conducted a prospective, uncontrolled, open-label multicenter study. A total of 30 chronic HCV-infected adolescents, aged from 12 to 17 years old were included and treated with dual SOF/DCV for 12 weeks. Patients were monitored throughout the treatment and follow-up period for safety and efficacy outcome measures including the sustained virologic response 12 (SVR12) rate. Results: The intention-to-treat (ITT) SVR12 rate was 29 of 30 (96.7%; 95% confidence interval [CI] 83.3%-99.4%). The only patient who did not achieve SVR12 was lost to follow-up after showing viral negativity at the end of treatment (EOT) visit. Whereas all the remaining 29 patients (100%, 95% CI 88.3%-100%) who completed the follow-up visits achieved SVR12. All patients showed normalized liver enzymes with normal hematological, liver and renal function tests at the end of the study. No fatalities or treatment-emergent serious or severe adverse events were reported throughout the study. Conclusions: SOF/DCV combined therapy could be a safe and effective treatment in adolescent patients 12 to 17 years old with chronic HCV genotype 4 infection. (See Video, Supplemental Digital Content, http://links.lww.com/MPG/B348). © 2018 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.


Keywords

adolescents; chronic hepatitis C; daclatasvir; efficacy; safety; sofosbuvir; Adolescent; Antiviral Agents; Child; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Prospective Studies; Sustained Virologic Response; Viral Load; alanine aminotransferase; aspartate aminotransferase; creatinine; hemoglobin; virus RNA; antivirus agent; BMS-790052; imidazole derivative; abdominal pain; antiviral therapy; Article; clinical article; cohort analysis; combination drug therapy; creatinine blood level; drug efficacy; drug safety; fatigue; follow up; headache; hemoglobin blood level; human; intention to treat analysis; kidney function; multicenter study; nausea; open study; outcome assessment; platelet count; priority journal; prospective study; pruritus; rash; school child; side effect; virus load; clinical trial


Citation Information

Scopus Citations: 42


For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.

The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.

English Website: https://www.tbri.sci.eg/en/

Arabic Website: https://www.tbri.sci.eg/ar/

Prepared and Uploaded by:

Abdalla F. Abdalla

Electronic Portal Unit

Electronic Portal Unit

Popular Posts

A cost-performance index for nano-optical biosensor evaluation: Systematic evaluation of europium–salicylate luminescent platforms for GPC3-targeted early HCC diagnosis

Interpretation of liver stiffness measurement in patients with mixed liver disease etiologies

Variable clinical presentations of pulmonary hydatid cysts: a four-case series from a single center in United Arab Emirates, non-endemic region

Holothuria arenicola Extract-Loaded Polycaprolactone Nanocapsules Attenuate Bile Duct Ligation-Induced Acute Liver Injury

Mytilus edulis-mediated green synthesis of selenium nanoparticles with antimicrobial and molluscicidal applications

Corrigendum to ‘Eco-friendly approach for the removal and simultaneous detection of cyanide toxins from drinking and wastewater sources’ [Environ. Pollut. 385 (2025) 127094]

Multifunctional polycaprolactone-based composite fibers with icariin and glutathione for effective repair of critical-sized bone defects